These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 1492223)

  • 21. A randomized trial of cisplatin, vinblastine, and bleomycin versus vinblastine, cisplatin, and etoposide in the treatment of advanced germ cell tumors of the testis: a Southwest Oncology Group study.
    Wozniak AJ; Samson MK; Shah NT; Crawford ED; Ford CD; Altman SJ; Stephens RL; Natale RB; Bouroncle BA; Blumenstein BA
    J Clin Oncol; 1991 Jan; 9(1):70-6. PubMed ID: 1702148
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Poorly differentiated carcinoma of unknown primary site: correlation of light microscopic findings with response to cisplatin-based combination chemotherapy.
    Hainsworth JD; Wright EP; Gray GF; Greco FA
    J Clin Oncol; 1987 Aug; 5(8):1275-80. PubMed ID: 2442318
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Carcinoma of unknown primary site.
    Greco FA; Burris HA; Erland JB; Gray JR; Kalman LA; Schreeder MT; Hainsworth JD
    Cancer; 2000 Dec; 89(12):2655-60. PubMed ID: 11135228
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effective radiochemotherapy with cisplatin and etoposide for the management of patients with locally inoperable and metastatic esophageal carcinoma.
    Hejna M; Kornek GV; Schratter-Sehn AU; Zach M; Schoder M; Raderer M; Rosen H; Schiessel R; Scheithauer W
    Cancer; 1996 Oct; 78(8):1646-50. PubMed ID: 8859175
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas.
    Iwasa S; Morizane C; Okusaka T; Ueno H; Ikeda M; Kondo S; Tanaka T; Nakachi K; Mitsunaga S; Kojima Y; Hagihara A; Hiraoka N
    Jpn J Clin Oncol; 2010 Apr; 40(4):313-8. PubMed ID: 20047862
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High dose intensity of cisplatin and etoposide in adenocarcinoma of unknown primary.
    Gill I; Guaglianone P; Grunberg SM; Scholz M; Muggia FM
    Anticancer Res; 1991; 11(3):1231-5. PubMed ID: 1888154
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Continuous infusion cisplatin and etoposide chemotherapy for cancer of unknown primary site (CUPS) in Taiwan, a region with a high prevalence of endemic viral infections.
    Liu JM; Chen YM; Chao Y; Liu SM; Tiu CM; Wu HW; Chiou TC; Hsieh RK; Chen LT; Whang-Peng J
    Jpn J Clin Oncol; 1998 Jul; 28(7):431-5. PubMed ID: 9739784
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase II study of cisplatin, etoposide and gemcitabine in an unfavourable group of patients with carcinoma of unknown primary site.
    Balaña C; Manzano JL; Moreno I; Cirauqui B; Abad A; Font A; Mate JL; Rosell R
    Ann Oncol; 2003 Sep; 14(9):1425-9. PubMed ID: 12954583
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Subsets of tumors responsive to cisplatin or carboplatin combinations in patients with carcinoma of unknown primary site. A Hellenic Cooperative Oncology Group Study.
    Pavlidis N; Kosmidis P; Skarlos D; Briassoulis E; Beer M; Theoharis D; Bafaloukos D; Maraveyas A; Fountzilas G
    Ann Oncol; 1992 Sep; 3(8):631-4. PubMed ID: 1450045
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epirubicin, cisplatin, and prolonged or brief infusional 5-fluorouracil in the treatment of carcinoma of unknown primary site.
    Karapetis CS; Yip D; Virik K; Strickland A; Ryder K; Cowling M; Harper PG
    Med Oncol; 2001; 18(1):23-32. PubMed ID: 11778966
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [A Case of Poorly Differentiated Carcinoma of Unknown Primary Site with Risk of Choriocarcinoma Syndrome Effectively Treated with Reduced Bleomycin,Cisplatin ,Etoposide Combination Regimen(BEP Regimen)].
    Okano M; Oda H; Ishihara M; Tamaru S; Saito K; Yamashita Y; Mizuno T; Katayama N
    Gan To Kagaku Ryoho; 2018 Apr; 45(4):643-645. PubMed ID: 29650822
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment with cisplatin and etoposide in patients with neuroendocrine tumors.
    Fjällskog ML; Granberg DP; Welin SL; Eriksson C; Oberg KE; Janson ET; Eriksson BK
    Cancer; 2001 Sep; 92(5):1101-7. PubMed ID: 11571721
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Successful treatment of metastatic thymic carcinoma with cisplatin, vinblastine, bleomycin, and etoposide chemotherapy.
    Carlson RW; Dorfman RF; Sikic BI
    Cancer; 1990 Nov; 66(10):2092-4. PubMed ID: 1699650
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metastatic adenocarcinoma of unknown primary site. A randomized study of two combination chemotherapy regimens.
    Milliken ST; Tattersall MH; Woods RL; Coates AS; Levi JA; Fox RM; Raghavan D
    Eur J Cancer Clin Oncol; 1987 Nov; 23(11):1645-8. PubMed ID: 2448145
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The management of patients with adenocarcinoma and poorly differentiated carcinoma of unknown primary site.
    Greco FA; Hainsworth JD
    Semin Oncol; 1989 Aug; 16(4 Suppl 6):116-22. PubMed ID: 2669133
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Are 3 cycles of bleomycin, etoposide and cisplatin or 4 cycles of etoposide and cisplatin equivalent optimal regimens for patients with good risk metastatic germ cell tumors of the testis? The need for a randomized trial.
    Culine S; Theodore C; Terrier-Lacombe MJ; Droz JP
    J Urol; 1997 Mar; 157(3):855-8; discussion 858-9. PubMed ID: 9072585
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown origin: favorable subsets of patients with unknown-primary carcinoma?
    Lenzi R; Hess KR; Abbruzzese MC; Raber MN; Ordoñez NG; Abbruzzese JL
    J Clin Oncol; 1997 May; 15(5):2056-66. PubMed ID: 9164218
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cisplatin and etoposide in advanced colorectal carcinoma.
    Passalacqua R; Bisagni G; Cocconi G; Boni C; Di Blasio B; Ceci G
    Ann Oncol; 1991 Oct; 2(9):687-8. PubMed ID: 1742225
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II trial of cisplatin and etoposide as first-line therapy in metastatic breast carcinoma.
    Lluch A; Azagra P; Cervantes A; Muñoz M; Alberola V; Santabarbara P; García-Conde J
    Oncology; 1994; 51(4):352-5. PubMed ID: 8208520
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alternative bimonthly cycles of doxorubicin, cyclophosphamide, and etoposide, cisplatin with hematopoietic growth factor support in patients with carcinoma of unknown primary site.
    Culine S; Fabbro M; Ychou M; Romieu G; Cupissol D; Pinguet F
    Cancer; 2002 Feb; 94(3):840-6. PubMed ID: 11857320
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.